Inventor · disambiguated record
Matthew Arnold Marx
Also filed as: MARX MATTHEW · MARX MATTHEW A · MARX MATTHEW ARNOLD
32 granted patents·30 pending applications·416 citations·filing 2000–2025
96Inventor score
Top patents by PatentIndex Score
62 records- 0197US10689377B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Jun 23, 2020·16 cites·57 claims
- 0296US11453683B1KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·13 cites·84 claims
- 0396US11091495B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·4 cites·26 claims
- 0496US10125134B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Nov 13, 2018·43 cites·9 claims
- 0596US6492383B1Thienopyrimidine and thienopyridine derivatives useful as anticancer agentsPFIZER·Filed 2000·Granted Dec 10, 2002·163 cites·25 claims
- 0693US10633381B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 28, 2020·8 cites·7 claims
- 0792US12421253B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·1 cites·29 claims
- 0892US11964989B2KRas G12D inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·2 cites·19 claims
- 0992US11220509B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jan 11, 2022·2 cites·27 claims
- 1091US11267812B2KRAS G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2017·Granted Mar 8, 2022·11 cites·34 claims
- 1191US10647715B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted May 12, 2020·10 cites·9 claims
- 1291US9809541B2LSD1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2016·Granted Nov 7, 2017·11 cites·62 claims
- 1390US7271262B2Pyrrolopyrimidine derivativesPFIZER·Filed 2003·Granted Sep 18, 2007·66 cites·61 claims
- 1489US11999753B2Tetrahydropyridopyrimidine pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Jun 4, 2024·1 cites·5 claims
- 1586US10266542B2EZH2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2018·Granted Apr 23, 2019·6 cites·40 claims
- 1684US11479551B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Oct 25, 2022·1 cites·30 claims
- 1784US6995171B2Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agentsAGOURON PHARMA·Filed 2002·Granted Feb 7, 2006·24 cites·21 claims
- 1882US11548888B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jan 10, 2023·1 cites·9 claims
- 1982US6964961B2Thiophene derivatives useful as anticancer agentsPFIZER·Filed 2001·Granted Nov 15, 2005·17 cites·21 claims
- 2082US2025282787A1SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORSMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2182US2024101553A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2281US11932633B2KRas G12C inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Mar 19, 2024·2 cites·41 claims
- 2380US12371435B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·20 claims
- 2478US2023373999A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2577US12304915B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Granted May 20, 2025·0 cites·81 claims
- 2677US2024309020A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2775US2025270220A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2872US2023054883A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2971US7595325B2Substituted pyrrolo[2,3-d]pyrimidine derivatives useful in cancer treatmentPFIZER·Filed 2005·Granted Sep 29, 2009·2 cites·6 claims
- 3071US7435739B2Substituted pyrrolopyrimidines useful in the treatment of cancerCHEN JINSHAN·Filed 2004·Granted Oct 14, 2008·12 cites·34 claims
- 3170US2025388606A1Azaquinazoline pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3268US12398154B2Azaquinazoline pan-KRas inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Granted Aug 26, 2025·0 cites·49 claims
- 3368US11492351B2MTA-cooperative PRMT5 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·0 cites·27 claims
- 3468US2020262837A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3567US11702418B2SOS1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Granted Jul 18, 2023·0 cites·72 claims
- 3667US2024391882A1Substituted QuinoxalinesMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3766US11485738B2Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitorsMIRATI THERAPEUTICS INC·Filed 2019·Granted Nov 1, 2022·0 cites·18 claims
- 3866US2025382290A1Salts of sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3964US2025368649A1Tetrahydropyridopyrimidine pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4064US2024025907A1QUINAZOLINE PAN-KRas INHIBITORSMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4163US2025376483A1Prodrugs of pan-kras inhibitorsMIRATI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4260US12252493B2Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancerMIRATI THERAPEUTICS INC·Filed 2020·Granted Mar 18, 2025·0 cites·27 claims
- 4360US2025179082A1Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancerMIRATI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4459US2024228510A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4559US2024368153A1Aminopyridine-based MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4659US2025059182A1Sos1 inhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4759US2020308170A1Kras g12c inhibitorsMIRATI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4857US2024208912A1MTA-Cooperative PRMT5 InhibitorsMIRATI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4957US2024034733A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5055US2023357277A1Kras g12d inhibitorsMIRATI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Matthew Arnold Marx files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →